JP2011521969A - 眼疾患を治療するためのＴＧＦ−β受容体阻害剤又はアクチビン様キナーゼ（ＡＬＫ）５阻害剤、Ａ−８３−０１及びＳＢ−４３１５４２の使用方法及び創傷治療条件 - Google Patents

眼疾患を治療するためのＴＧＦ−β受容体阻害剤又はアクチビン様キナーゼ（ＡＬＫ）５阻害剤、Ａ−８３−０１及びＳＢ−４３１５４２の使用方法及び創傷治療条件 Download PDF

Info

Publication number
JP2011521969A
JP2011521969A JP2011511843A JP2011511843A JP2011521969A JP 2011521969 A JP2011521969 A JP 2011521969A JP 2011511843 A JP2011511843 A JP 2011511843A JP 2011511843 A JP2011511843 A JP 2011511843A JP 2011521969 A JP2011521969 A JP 2011521969A
Authority
JP
Japan
Prior art keywords
composition
kinase
inhibitor
activin receptor
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011511843A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011521969A5 (https=
Inventor
中村，弘
ユエ，ベアトリス，ワイ．，ジェイ．，ティー．
Original Assignee
スムマ ヘルス システムズ エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スムマ ヘルス システムズ エルエルシー filed Critical スムマ ヘルス システムズ エルエルシー
Publication of JP2011521969A publication Critical patent/JP2011521969A/ja
Publication of JP2011521969A5 publication Critical patent/JP2011521969A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2011511843A 2008-05-30 2009-05-29 眼疾患を治療するためのＴＧＦ−β受容体阻害剤又はアクチビン様キナーゼ（ＡＬＫ）５阻害剤、Ａ−８３−０１及びＳＢ−４３１５４２の使用方法及び創傷治療条件 Pending JP2011521969A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5746108P 2008-05-30 2008-05-30
US61/057,461 2008-05-30
PCT/US2009/045607 WO2009146408A1 (en) 2008-05-30 2009-05-29 Methods for using tgf-b receptor inhibitors or activin-like kinase (alk) 5 inhibitors a-83-01 and sb-431542 to treat eye disease and wound healing conditions

Publications (2)

Publication Number Publication Date
JP2011521969A true JP2011521969A (ja) 2011-07-28
JP2011521969A5 JP2011521969A5 (https=) 2011-09-08

Family

ID=41377599

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011511843A Pending JP2011521969A (ja) 2008-05-30 2009-05-29 眼疾患を治療するためのＴＧＦ−β受容体阻害剤又はアクチビン様キナーゼ（ＡＬＫ）５阻害剤、Ａ−８３−０１及びＳＢ−４３１５４２の使用方法及び創傷治療条件

Country Status (5)

Country Link
US (1) US20100087486A1 (https=)
EP (1) EP2285380A4 (https=)
JP (1) JP2011521969A (https=)
CN (1) CN102083439A (https=)
WO (1) WO2009146408A1 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010121162A1 (en) * 2009-04-17 2010-10-21 Summa Health Systems Llc Use of transforming growth factor-b receptor inhibitors to suppress ocular scarring
CN103167875A (zh) * 2010-08-17 2013-06-19 阿勒根公司 用于治疗角膜浑浊的ep2或ep4激动剂
NZ707477A (en) 2012-11-02 2019-09-27 Celgene Corp Activin-actrii antagonists and uses for treating bone and other disorders
JP6461787B2 (ja) 2013-04-12 2019-01-30 国立大学法人京都大学 肺胞上皮前駆細胞の誘導方法
US9822342B2 (en) 2013-05-14 2017-11-21 Kyoto University Method of efficiently inducing cardiomyocytes
MX386503B (es) 2013-07-30 2025-03-19 Kyoto Prefectural Public Univ Corp Medicamentos terapeuticos de matriz extracelular endotelial corneal.
WO2015020113A1 (ja) 2013-08-07 2015-02-12 国立大学法人京都大学 膵ホルモン産生細胞の製造法
AU2014316100B2 (en) 2013-09-05 2020-11-05 Eisai R&D Management Co., Ltd. New method for inducing dopamine-producing neural precursor cells
CA2927898C (en) * 2013-10-31 2021-11-16 Kyoto Prefectural Public University Corporation Therapeutic drug for diseases related to endoplasmic reticulum cell death in corneal endothelium
CN106536718B (zh) 2014-05-21 2021-04-27 国立大学法人京都大学 胰芽细胞的制造方法及含有胰芽细胞的胰疾病治疗剂
CA3005975A1 (en) 2015-11-23 2017-06-01 Acceleron Pharma Inc. Methods for treating eye disorders
CA3021628A1 (en) 2016-04-22 2017-10-26 Kyoto University Method for producing dopamine-producing neural precursor cells
CN106282092A (zh) * 2016-09-07 2017-01-04 山东省眼科研究所 一种角膜内皮分离和扩增培养液
JP7161775B2 (ja) 2017-05-25 2022-10-27 国立大学法人京都大学 中間中胚葉細胞から腎前駆細胞への分化誘導方法、および多能性幹細胞から腎前駆細胞への分化誘導方法
EP3757208A4 (en) 2018-02-19 2021-12-01 Sumitomo Dainippon Pharma Co., Ltd. CELL UNIT, MIXTURE OF CELL UNITS AND METHOD OF MANUFACTURING THEREOF
WO2020022261A1 (ja) 2018-07-23 2020-01-30 国立大学法人京都大学 新規腎前駆細胞マーカーおよびそれを利用した腎前駆細胞の濃縮方法
JP7700673B2 (ja) 2019-05-15 2025-07-01 味の素株式会社 神経堤細胞または角膜上皮細胞の純化方法
CA3141455A1 (en) 2019-05-20 2020-11-26 Ajinomoto Co., Inc. Expansion culture method for cartilage or bone precursor cells
CN114375328B (zh) 2019-09-06 2024-12-27 学校法人庆应义塾 包含胶质前体细胞的细胞聚集体的制备方法
CN118726239A (zh) 2019-10-01 2024-10-01 国立大学法人京都大学 输尿管芽顶端部细胞的分离方法
JP7785351B2 (ja) 2020-03-19 2025-12-15 オリヅルセラピューティクス株式会社 心筋細胞の精製方法
AU2021239654A1 (en) 2020-03-19 2022-10-27 Orizuru Therapeutics, Inc. Cardiomyocyte purification method
US20230256024A1 (en) 2020-07-13 2023-08-17 Kyoto University Skeletal muscle precursor cells and method for purifying same, composition for treating myogenic diseases, and method for producing cell group containing skeletal muscle precursor cells
CN116802276A (zh) 2021-01-08 2023-09-22 国立大学法人京都大学 用于扩增培养肾元祖细胞的培养基、扩增培养肾元祖细胞的方法以及肾脏类器官的制造方法
EP4353243A4 (en) 2021-06-10 2025-06-25 Ajinomoto Co., Inc. METHOD FOR PRODUCING MESENCHYMAL STEM CELLS
AU2022294563A1 (en) 2021-06-17 2024-01-18 Kyoto University Method for producing cerebral cortical cell preparation derived from human pluripotent stem cells
WO2023286852A1 (ja) 2021-07-15 2023-01-19 株式会社セルファイバ 構造体及びその用途
EP4386083A4 (en) 2021-08-11 2025-11-12 Univ Kyoto METHOD FOR PRODUCING RENAL INTERSTITIAL PROGENITOR CELLS, ERYTHROPOIETIN-PRODUCING CELLS AND METHOD FOR PRODUCING RENIIN-PRODUCING CELLS
EP4471126A4 (en) 2022-02-01 2026-01-14 Univ Kyoto LUNG MESENCHYMAL CELLS AND PROCESS FOR PRODUCING LUNG MESENCHYMAL CELLS
EP4477746A4 (en) 2022-02-09 2026-02-18 Racthera Co Ltd METHOD FOR EVALUATING THE DIFFERENTIATION POTENTIAL OF CELLS IN A CULTURE BROTH IN THE DIFFERENCE OF MULTIPOTENTED STEM CELLS INTO NEURAL CELLS OF THE MENSCEPHAL FLOOR PLAQUE REGION
EP4530344A1 (en) 2022-05-23 2025-04-02 Kyoto University Production method for renal collecting duct cells and pelvic epithelial cells
CN119948151A (zh) 2022-09-26 2025-05-06 国立大学法人京都大学 胰腺内胚层细胞的制造方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005527590A (ja) * 2002-04-04 2005-09-15 バイオジェン， インコーポレイテッド 三置換ヘテロアリールおよびそれらを製造し使用する方法
JP2007533734A (ja) * 2004-04-21 2007-11-22 アイエヌ２ジェン カンパニー リミテッド Ａｌｋ５及び／又はａｌｋ４の抑制剤としての２−ピリジル置換イミダゾール類
WO2008006583A1 (en) * 2006-07-14 2008-01-17 Novartis Ag Pyrimidine derivatives as alk-5 inhibitors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5470881A (en) * 1993-09-09 1995-11-28 West Virginia University Research Corporation Urea ophthalmic ointment and solution
US5449671A (en) * 1993-09-29 1995-09-12 Alcon Laboratories, Inc. Use of TGF-β3, to prevent or retard fistula closure following glaucoma filtration surgery
AU7846894A (en) * 1993-09-29 1995-04-18 Alcon Laboratories, Inc. Compositions containing growth factors and antiplastic agents
CA2149528A1 (en) * 1993-09-29 1995-04-06 Billie M. York Compositions containing growth factors and antimetabolites
US5486534A (en) * 1994-07-21 1996-01-23 G. D. Searle & Co. 3,4-substituted pyrazoles for the treatment of inflammation
US6063396A (en) * 1994-10-26 2000-05-16 Houston Biotechnology Incorporated Methods and compositions for the modulation of cell proliferation and wound healing
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
WO2003057670A2 (en) * 2001-12-28 2003-07-17 Guilford Pharmaceuticals Inc. Indoles as naaladase inhibitors
US7361669B2 (en) * 2003-01-02 2008-04-22 Millennium Pharmaceuticals, Inc. Compositions and method for inhibiting TGF-β
ES2305744T3 (es) * 2003-03-12 2008-11-01 Millennium Pharmaceuticals, Inc. Derivados de quinazolina como inhibidores e tgf-beta.
WO2004112710A2 (en) * 2003-06-17 2004-12-29 Millennium Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR INHIBITING TGF-ß
US20050256118A1 (en) * 2004-05-12 2005-11-17 Altenbach Robert J Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
US7098222B2 (en) * 2004-05-12 2006-08-29 Abbott Laboratories Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
US20060234911A1 (en) * 2005-03-24 2006-10-19 Hoffmann F M Method of reversing epithelial mesenchymal transition
WO2007070866A2 (en) * 2005-12-16 2007-06-21 Alcon, Inc. Control of intraocular pressure using alk5 modulation agents
US7524640B2 (en) * 2006-08-06 2009-04-28 Children's Medical Center Corporation Inhibiting Smad2/3 signaling promotes neurite outgrowth in dorsal root ganglia

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005527590A (ja) * 2002-04-04 2005-09-15 バイオジェン， インコーポレイテッド 三置換ヘテロアリールおよびそれらを製造し使用する方法
JP2007533734A (ja) * 2004-04-21 2007-11-22 アイエヌ２ジェン カンパニー リミテッド Ａｌｋ５及び／又はａｌｋ４の抑制剤としての２−ピリジル置換イミダゾール類
WO2008006583A1 (en) * 2006-07-14 2008-01-17 Novartis Ag Pyrimidine derivatives as alk-5 inhibitors

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
JPN6013041065; Ｌｉｕ　Ｘｉｎｇ-Ｊｕｎ　ｅｔ　ａｌ．: Ｂｉｏｔｅｃｈｎｏｌｏｇｙ　ｌｅｔｔｅｒｓ Ｖｏｌ．２７，　Ｎｏ．２０, 2005, ｐ．１６０９-１５ *
JPN6013041067; Ｔｏｊｏ，Ｍ．　ｅｔ　ａｌ．: Ｃａｎｃｅｒ　ｓｃｉｅｎｃｅ Ｖｏｌ．９６，　Ｎｏ．１１, 2005, ｐ．７９１-８００ *
JPN6013041069; 雑賀司珠也: 臨床眼科 Ｖｏｌ．６１，　Ｎｏ．２, 2007, ｐ．１５６-１６３ *
JPN6013041072; 新田信一: あたらしい眼科 Ｖｏｌ．１８，　Ｎｏ．１, 2001, ｐ．３-７ *
JPN6013041074; 高橋保志: 医薬ジャーナル Ｖｏｌ．３４，　増刊号, 1998, ｐ．２３７-２４２ *

Also Published As

Publication number Publication date
WO2009146408A9 (en) 2010-12-02
US20100087486A1 (en) 2010-04-08
WO2009146408A1 (en) 2009-12-03
CN102083439A (zh) 2011-06-01
EP2285380A4 (en) 2012-03-14
EP2285380A1 (en) 2011-02-23

Similar Documents

Publication Publication Date Title
JP2011521969A (ja) 眼疾患を治療するためのＴＧＦ−β受容体阻害剤又はアクチビン様キナーゼ（ＡＬＫ）５阻害剤、Ａ−８３−０１及びＳＢ−４３１５４２の使用方法及び創傷治療条件
JP7571171B2 (ja) 翼状片を治療するための組成物及び方法
JP2012524073A (ja) 眼球瘢痕化を抑制するための形質転換成長因子−β受容体阻害剤の使用
Morales et al. Intraoperative mitomycin and corneal endothelium after photorefractive keratectomy
JP7730816B2 (ja) 過剰血管新生に関連する眼疾患を治療する化合物
TWI720582B (zh) ＶＥＧＦ和ＴＧＦβ的多激酶抑制劑及其用途
CN109996814B (zh) 多激酶抑制剂及在眼部纤维化中的用途
CN105050600B (zh) 眼底疾病治疗剂
JPH02501483A (ja) 緑内症または高眼圧症治療剤
EP3808352A1 (en) Use of salidroside and derivative thereof in preparation of inhibitor medicament for diseases of ophthalmic fibrosis caused by abnormalities of extracellular matrix proteins
KR20010040457A (ko) 안약 조성물
JP2016514123A (ja) ジピリダモールを用いる眼疾患の治療において使用するための組成物
JP6861634B2 (ja) 眼疾患を処置するための組成物及び方法
Ianchulev Suprachoroidal space as a therapeutic target
WO2007050720A1 (en) Loteprednol etabonate against vascular dysfunction in the eye
JPH08503968A (ja) 増殖因子と代謝拮抗物質を含有する組成物
TW201717958A (zh) 眼壓下降增強劑
Gillies et al. Topical interferon alpha 2b for corneal haze after excimer laser photorefractive keratectomy
WO2019117813A1 (en) Focal adhesion kinase targeted therapeutics for the treatment of glaucoma and fibrosis
Wang et al. AGTR1 blocker attenuates activation of Tenon's capsule fibroblasts after glaucoma filtration surgery via the NF-κB signaling pathway
EP4284507A1 (en) Methods of treating ocular fibrotic pathologies
JP7580123B2 (ja) 血管新生関連疾患の予防又は治療用医薬組成物
JP7429500B2 (ja) 角膜上皮障害治療剤
KR102068697B1 (ko) 염증성 안구표면질환의 예방 또는 치료용 조성물
Dubey et al. Management of neovascular glaucoma

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110526

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120412

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130828

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140212